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RESUMO
Introdução: A quimioembolização hepática é uma técnica amplamente usada para o tratamento do carcinoma hepatocelular. A princi-
pal complicação deste procedimento é a síndrome pós-quimioembolização. O principal objetivo deste estudo foi determinar fatores de 
risco para síndrome pós-quimioembolização. 
Material e Métodos: Análise retrospetiva unicêntrica de 563 procedimentos de quimioembolização hepática efetuados entre 1/1/2014-
31/12/2015. A quimioembolização hepática foi efetuada com ½ - 2 ampolas de microesferas 100 - 300 μm carregadas com doxorrubi-
cina. Os pacientes que desenvolveram síndrome pós-quimioembolização foram identificados pelo prolongamento do internamento por 
dor, febre, náuseas e/ou vómitos. Um grupo controlo com os pacientes que não desenvolveram síndrome pós-quimioembolização foi 
criado de forma randomizada (três controlos para um caso). Foi realizada análise descritiva e regressão logística multivariada. 
Resultados: A prevalência global de síndrome pós-quimioembolização foi 6,2%. Quimioembolização hepática com dose de doxorrubi-
cina superior a 75 mg (mais de uma ampola), o tamanho do nódulo maior e o género feminino demonstraram relação estatisticamente 
significativa com o desenvolvimento de síndrome pós-quimioembolização (p = 0,030, p = 0,046 e p = 0,037, respetivamente).
Discussão: Doses de doxorrubicina superiores a 75 mg estão associadas a maior risco de síndrome pós-quimioembolização. Este 
resultado pode ter impacto na prática clínica, sempre que for possível evitar doses maiores sem comprometer a eficácia do tratamento. 
O tamanho do maior nódulo tratado e o género feminino também constituem fatores de risco para síndrome pós-quimioembolização. 
As outras variáveis estudadas não demonstraram relação com síndrome pós-quimioembolização.
Conclusão: A dose de doxorrubicina, o tamanho do maior nódulo tratado e o género feminino são potenciais fatores de risco para o 
desenvolvimento de síndrome pós-quimioembolização após quimioembolização hepática para o tratamento de carcinoma hepatoce-
lular. 
Palavras-chave: Carcinoma Hepatocelular; Factores de Risco; Quimioembolização Terapêutica; Radiologia de Intervenção
ABSTRACT
Introduction: Hepatic transarterial chemoembolization is a widely used technique for the treatment of hepatocellular carcinoma. The 
most common complication of this procedure is postembolization syndrome. The main objective of this study was to assess risk factors 
for the development of postembolization syndrome.
Material and Methods: Single-centre retrospective analysis of 563 hepatic transarterial chemoembolization procedures from January 
1st, 2014 – December 31st, 2015. Hepatic transarterial chemoembolization was performed with ½ - 2 vials of 100 - 300 μm microspheres 
loaded with doxorubicin. Patients who experienced postembolization syndrome were identified based on prolongation of hospitalization 
due to pain, fever, nausea and/or vomiting. A control group with the patients who did not have postembolization syndrome was randomly 
created (three controls for one case). Descriptive analysis and multivariate logistic regression were performed.
Results: The overall prevalence of postembolization syndrome was 6.2%. Hepatic transarterial chemoembolization with doxorubicin 
dosage above 75 mg (more than one vial), the size of the largest nodule and female gender had statistically significant relation with 
development of postembolization syndrome (p = 0.030, p = 0.046 and p = 0.037, respectively). 
Discussion: Doxorrubicin dosage above 75 mg is associated with a higher risk of postembolization syndrome. This result can be 
helpful for decision-making in clinical practice, whenever it is possible to avoid a higher dose without compromising the efficacy of 
the treatment. The size of the largest nodule and female gender also constitute risk factors for postembolization syndrome. The other 
variables studied were not related to the development of postembolization syndrome.
Conclusion: The dose of doxorrubicin, the size of the largest nodule treated and female gender are potential risk factors for the 
development of postembolization syndrome after hepatic transarterial chemoembolization for hepatocellular carcinoma.
Keywords: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Radiology, Interventional; Risk Factors
INTRODUCTION
 Hepatocellular carcinoma (HCC) constitutes the 
sixth most common cancer worldwide and the third most 
common cause of cancer death.1 The majority of patients 
with HCC have underlying cirrhosis (80% to 90%) and it 
constitutes the leading cause of death in these patients.2 
The available treatments for HCC are: resection, 
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transplantation, ablation, transarterial chemoembolization 
(TACE) and sorafenib.3 The Barcelona Clinic Liver Cancer 
(BCLC) staging and treatment strategy defines the best 
therapeutic approach for HCC according to staging, which 
depends on tumor characteristics and performance status 
(including liver function).4 In the intermediate stage BCLC 
B (multinodular liver in a patient with Child-Pugh A-B and 
Performance Status 0), the treatment of choice is TACE, 
which is palliative.3 Unfortunately, many of the patients 
are diagnosed at this stage and later ones.4 Furthermore, 
patients at an earlier stage (specially BCLC A) may benefit 
from TACE when there is failure of the first line therapeutic 
approach or recurrence.3
 TACE is a procedure that consists in the local delivery of 
a high dose of chemotherapeutic drug to the tumor, which 
can be associated with particulate and/or oily embolization 
of its feeding arteries.5 Although it is a minimally invasive 
technique, it is associated with possible complications. 
Because it causes a hypoxic insult to the HCC and also 
the surrounding liver tissue, postembolization syndrome 
(PES) is the most common adverse event.6 It is thought 
to result from therapeutic cytotoxity, tumor ischemia and 
resulting intrahepatic and extrahepatic inflammation7 and 
is manifested by fever, malaise, right upper quadrant pain, 
nausea and vomiting.8 Its reported incidences vary widely in 
the literature and it has been described in as many as 60%-
80% of patients.6,9 The symptoms usually develop 24 - 72 
hours after the procedure and PES is generally self-limited 
and can be treated conservatively. It usually resolves in 
approximately a week.7 Nevertheless, PES constitutes the 
main factor affecting the need and length of postprocedural 
hospitalization.5,9 
 The main objective of this study is to assess risk factors 
for the development of PES, either related to the patient, the 
characteristics of the tumor or the procedure itself.
MATERIAL AND METHODS
Participants 
 Between January 1st, 2014 and December 31st, 2015, 
a total of 563 TACE procedures for HCC treatment were 
conducted in our institution. The decision of which patients 
should perform TACE procedures was taken during a weekly 
multidisciplinary team meeting that included surgeons, 
hepatologists and radiologists.
 The total number of patients submitted to this procedure 
was 276 (some patients underwent the procedure more than 
once during this period). All the patients subjected to TACE 
were included in the study. The gender distribution was 25 
females and 251 males. The mean age of the patients at 
the time of procedure was 65 years (maximum 89, minimum 
35). 
 The most frequent cause of cirrhosis was alcohol-
related liver disease, which accounted for 44% of the 
patients (121 patients). Other common cause of cirrhosis 
was viral infection: there were 50 patients (18%) with 
hepatitis C virus (HCV) infection alone and 51 patients 
(18%) with both HCV infection and alcohol abuse. There 
were also 12 patients (4%) with cirrhosis related to hepatitis 
B virus (HBV), 3 patients with both HBV virus infection and 
alcohol abuse, 4 patients with HBV plus HCV infection and 
one patient with all these three factors combined (HBV + 
HCV + alcohol abuse). Hemochromatosis was the cause of 
cirrhosis in 3 patients, and there were also 3 patients with 
hemochromatosis plus alcohol abuse and one patient with 
hemochromatosis and HCV infection. Non-alcoholic fatty 
liver disease (NASH) was the cause of cirrhosis in 5 patients 
and there were also 4 cases of cryptogenic cirrhosis and 
one case of auto-immune cirrhosis. Three patients with non-
cirrhotic livers on biopsy developed HCC. There were 14 
clinical charts in which the cause of cirrhosis was not clear.
 The median model for end-stage liver disease (MELD) 
score was 9 (range 6 - 20). Regarding the Child-Pugh 
classification, 85.1% of the patients were classified as 
Child’s class A and 14.9% were classified as Child’s class B. 
 All the patients were admitted to the hospital the day 
before the procedure. In this day, they performed laboratory 
blood tests that included complete blood count, prothrombin 
time (PT), international normalized ratio (INR) and 
biochemical tests, including total bilirubin and creatinine.
 The patients submitted to TACE procedures maintained 
a follow-up medical appointment in our centre with a 
hepatobiliary surgeon. All of the patients had an appointment 
one and three months after the procedure. 
Drug-eluting microspheres transarterial chemoemboli-
zation (DEM-TACE) procedure
 The TACE procedure was done transfemorally. The 
femoral artery was punctured according to the Seldinger 
method. After progression of a 5-Fr Simmons catheter 
(Cordis, Cardinal Health, San Francisco, CA, USA) into the 
relevant hepatic artery, the feeding artery was selectively 
catheterized with a 2.7F microcatheter (Progreat, Terumo, 
Tokyo, Japan). Between 1/2 and 2 vials of 100 - 300 μm 
microspheres loaded with doxorubicin (DC Beads, 
Biocompatibles, Farnham, Surrey, UK) were selectively 
administered. The dose administered depended on the 
size and vascularity of the territory treated. In some cases, 
additional embolics were used: lipiodol and/or polyvinyl 
alcohol (PVA) particles 150 - 350 micron (Contour, Boston 
Scientific, Natick, MA, USA). All patients were submitted 
to prophylactic antibiotic therapy with cephazolin 2 g i.v. 
immediately before the procedure. 
Data collection
 We retrospectively analysed the clinical charts of all the 
patients submitted to TACE to find possible complications. 
The analysis of the clinical charts included the hospitalization 
length, the inpatient and outpatient records, emergency 
department visits and need for re-hospitalization in the post-
procedural period. 
 In this study, PES was defined as prolongation of 
hospital stay above the usual hospitalization length for this 
type of procedure in our institution (two days), or need for 
emergency department visit and/or re-hospitalization in 
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Figure 1 – On the left computed tomography axial reconstruction (A), we can see a hepatic abscess that developed after trans-arterial 
chemoembolization. The right image of the same computed tomography (B) shows a perihepatic abscess, which deviates the lesser 
curvature of the stomach.
A B
the post-procedural period (first month), associated with 
abdominal pain, fever, nausea and/or vomiting. 
 Procedures followed by PES comprised the cases 
group. Three patients who developed PES were excluded 
from the cases group because of incomplete data. There 
were 32 procedures included in the cases group. A control 
group with the patients who did not have PES was randomly 
created, with a proportion of three controls for one case (96 
procedures).  
 Registered variables for each TACE procedure were: 
age and gender of the patient; previous TACE procedures; 
number of nodules treated; size of the largest nodule; dose 
of doxorubicin administered (number of vials); administration 
of additional embolics (lipiodol and/or PVA particles); blood 
laboratory tests including total bilirubin, creatinine, albumin; 
INR; Child-Pugh and MELD scores; presence of ascites; 
embolization of the cystic artery; and segmental portal vein 
thrombosis. 
Data analysis
 Statistical analysis of the data was performed using 
IBM SPSS Statistics 23.0. Association between different 
categorical variables and the development of PES was 
evaluated using chi-square (Pearson) test. For variables 
with cells with expected count less than 5, Fisher’s exact test 
was used instead. Continuous variables were studied with 
t-test for independent samples and Mann-Whitney test. The 
Mann-Whitney test was performed to study the continuous 
variables that did not show a normal distribution, neither in 
the Shapiro-Wilk test, nor in the normal Q-Q plot. Multivariate 
logistic regression was also performed. A p-value less than 
0.05 was considered statistically significant. 
RESULTS
 There were 45 complications registered in 41 procedures 
among the total of 563 TACE procedures analysed. These 
complications are described in Table 1. PES was the most 
common complication and occurred in 35 procedures, which 
Table 1 – Trans-arterial chemoembolization complications. This table indicates the number of complications observed after TACE 
procedure, the corresponding percentage for the total number of complications and also the percentage for the total number of procedures. 
Some patients had more that one of the complications listed. 
Complication n % per complicated procedures
% overall TACE* 
procedures
PES† 35 85.4% 6.20%
Hepatitis 2 4.9% 0.36%
Worsening renal function 2 4.9% 0.36%
Acute limb ischaemia 1 2.4% 0.18%
Acute pulmonary edema 1 2.4% 0.18%
Ascites 1 2.4% 0.18%
Encephalopathy 1 2.4% 0.18%
Hepatic abscess with sepsis 1 2.4% 0.18%
Puncture site hematoma 1 2.4% 0.18%
* Transarterial chemoembolization (TACE); † Postembolization syndrome (PES)
Lima M, et al. Risk factors for postembolization syndrome after transarterial chemoembolization, Acta Med Port 2018 Jan;31(1):22-29
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corresponds to 6.2% of the procedures and accounted for 
85.4% of all the complicated procedures after TACE. Four 
patients experienced more than one complication in the 
same TACE procedure: one patient had PES and worsening 
renal function, two patients had PES and hepatitis 
(asymptomatic elevation of aminotransferases) and another 
patient had ascites and worsening renal function. Other 
complications were isolated occurrences that included 
acute limb ischaemia, acute pulmonary edema, ascites, 
encephalopathy and puncture site hematoma.
 There was one death related to the procedure. 
This patient returned to the hospital four days after the 
procedure with fever and CT scan showed the presence 
of a hepatic abscess and also a perihepatic abscess that 
deviated the lesser curvature of the stomach (Fig. 1). This 
patient had a previous biliodigestive anastomosis (Fig. 2). 
He developed sepsis and he was admitted in the intensive 
Figure 2 – Computed tomography scan showing the presence of 
metallic suture staples of hepaticojejunostomy
Table 2 – Categorical variables: Chi-square (Pearson)/Fisher test. This table shows the number of procedures in each category for 
both cases and controls, the respective percentage and the p-value of Pearson/Fisher tests. A p-value less than 0.05 was considered 
statistically significant. 
Variables Cases (PES)*Total: 32
Controls
Total: 96 p
Gender (n; %)
  Female 
  Male
5; 15.6
27; 84.4
7; 7.3
89; 92.7 0.173
Previous TACE† procedures (n; %)
  Yes
  No
14; 43.8
18; 56.2
54; 56.2
42; 43.8 0.220
Number of nodules treated (n; %)
  < 5
  ≥ 5
29; 90.6
3; 9.4
90; 95.7
4; 4.3 0.369
Size of the largest nodule (n; %)
  ≤ 50 mm
  > 50 mm
26; 81.2
6; 18.8
75; 79.8
19; 20.2 0.858
Doxorubicin dose - number of vials (n; %)
  ≤ 1 vial
  > 1 vial
13; 40.6
19; 59.4
60; 62.5
36; 37.5 0.030
Lipiodol (n; %)
  Yes 
  No
4; 12.5
28; 87.5
17; 17.7
79; 82.3 0.491
PVA‡ particles (n; %)
  Yes
  No
3; 9.4
29; 90.6
10; 10.4
86; 89.6 1.000
Ascites (n; %)
  Yes
  No
4; 12.5
28; 87.5
12; 12.5
84; 87.5 1.000
Segmental portal vein thrombosis (n; %) 
  Yes
  No
4; 12.5
28; 87.5
7; 7.3
89; 92.7 0.465
Child-Pugh score (n; %)
  A
  B
27; 84.4
5; 15.6
82; 85.4
14; 14.6 1.000
MELD§ score (n; %)
  ≤ 10
  > 10
22; 68.8
10; 31.2
73; 76.0
23; 24.0 0.414
Embolization of the cystic artery (n; %)
  Yes
  No
2; 6.2
30; 93.8
1; 1.0
95; 99.0 0.154
* Postembolization syndrome (PES); † Transarterial chemoembolization (TACE); ‡ Polyvinyl alcohol (PVA); § Model for end-stage liver disease (MELD)
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care unit. The therapeutic measures that were provided 
were percutaneous ultrasound-guided drainage of the 
largest collection (perihepatic) and antibiotic therapy with 
piperacillin/tazobactam followed by meropenem. Despite 
that, the patient died approximately a week after the re-
hospitalization.
 The clinical outcome of all other patients was favourable, 
only with conservative treatments.
 Table 2 shows the results of the analysis of categorical 
variables with chi-square/Fisher tests. The majority of 
procedures consisted of the treatment of less than five 
nodules, both in the cases (90.6%) and control (95.7%) 
groups. There was a statistically significant difference 
between the two groups for the doxorubicin dose: the 
proportion of procedures in which it was administered more 
than one vial (dosage above 75 mg) was significantly higher 
in the PES group, with a p value of 0.030. For all the other 
categorical variables (namely the use of additional embolic 
agents, Child-Pugh and MELD scores, ascites, segmental 
portal vein thrombosis and embolization of the cystic artery) 
there were no statistically significant differences between 
the two groups using chi-square (Pearson) test/Fisher’s 
exact test. There were only three procedures that resulted 
in embolization of the cystic artery (two in the cases group 
and one in the control group). Although the proportion of 
patients who had a previous TACE procedure was lower 
in the case group (43.8%) when compared with the control 
group (56.2%), there were no statistically significant 
differences between them, both with parametric and non-
parametric tests.
 In Table 3 we can see the results of the t-test for 
independent samples for the analysis of continuous 
variables. The mean age of the patients was 64 years in 
the PES group and 66 years in the control group. There 
were no statistically significant differences between the two 
groups using t-test for all continuous variables, including 
the size of the largest nodule. However, the mean size was 
higher in the PES group (41.50 mm) when compared to the 
Table 3 – Continuous variables: t-test for independent samples. In this table we can see the mean ± standard deviation for the continuous 
variables in the cases and control groups and the p-value of t-test for independent samples. A p-value less than 0.05 was considered 
statistically significant. 
Variables Cases(PES)* Controls p
Age 64.09 ± 10.18 66.08 ± 9.69 0.323
Size of the largest nodule (mm) 41.50 ± 18.70 35.85 ± 20.64 0.174
Total bilirrubin (mg/dL) 0.92 ± 0.55 1.00 ± 0.49 0.480
Albumine (g/dL) 3.71 ± 0.45 3.73 ± 0.56 0.850
INR† 1.14 ± 0.15 1.14 ± 0.14 0.819
Creatinine (mg/dL) 1.00 ± 0.68 0.95 ± 0.37 0.581
Values in mean ± standard deviation; * Postembolization syndrome (PES); † International normalized ratio (INR)
Table 4 – Multivariate logistic regression. This table shows the results for multivariate logistic regression, namely the odds ratio, the 
confidence interval and p-values. A p-value less than 0.05 was considered statistically significant. 
Variables OR|| Confidence interval (95%) p
Gender 6.848 1.119 – 41.910 0.037
Previous TACE* procedures 0.340 0.069 – 1.669 0.184
Number of nodules treated 0.998 0.617 – 1.615 0.994
Size of the largest nodule (mm) 1.013 0.986 – 1.040 0.364
Doxorubicin dose (number of vials) 2.426 0.728 – 8.087 0.149
Lipiodol 0.269 0.049 – 1.491 0.133
PVA† particles 0.610 0.292 – 5.011 0.572
Total bilirrubin (mg/dL) 1.211 0.293 – 5.011 0.791
Albumine (g/dL) 1.389 0.356 – 5.416 0.636
INR‡ 0.436 0.003 – 63.286 0.744
Creatinine (mg/dL) 2.391 0.268 – 21.318 0.435
Ascites 0.434 0.053 – 3.569 0.437
Segmental portal vein thrombosis 3.166 0.659 – 15.217 0.150
Child-Pugh score 1.229 0.468 – 3.224 0.676
MELD§ score 0.855 0.598 – 1.224 0.394
Embolization of the cystic artery 5.833 0.278 – 122.505 0.256
* Trans-arterial chemoembolization (TACE); † Polyvinyl alcohol (PVA); ‡ International normalized ratio (INR); § Model for end-stage liver disease (MELD); || Odds ratio (OR)
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control group (35.85 mm). Since this variable did not show a 
normal distribution, we used the Mann-Whitney test. In this 
analysis, we found a statistically significant higher size of 
the largest nodule in the PES group (p = 0.046).
 Table 4 shows the results of the multivariate logistic 
regression. In this analysis we found a statistically significant 
difference between the two groups for gender, with a higher 
proportion of females in the PES group (p = 0.037). There 
were no statistically significant differences for the other 
variables studied.
DISCUSSION
 TACE constitutes a generally well-tolerated procedure. 
The incidence of major complications is described in 
the literature as 2% to 7%5,8 and the risk of death is 
approximately 1%.8 We had one death among all the 
procedures (563), which corresponds to a mortality rate 
of 0.18%. It occurred in a patient who developed hepatic 
and perihepatic abscesses and sepsis after the procedure. 
Infectious complications are rare after TACE because of 
antiseptic measures6 and the incidence of liver abscess is 
described in literature as 0.26%.10 However, the incidence 
of post TACE liver abscess is higher among patients with 
bilio-enteric anastomoses,11 which was the case of this 
patient. 
 The overall incidence of PES varies in the literature 
and is described to occur in up to 60% - 80%.6,9 In this 
study we found an incidence of PES of only 6.2%. Some 
studies show that the complication rates (including the 
incidence of PES) are similar when comparing doxorubicin 
drug-eluting beads TACE (DEM-TACE) with conventional 
TACE.12,13 A study from Odisio et al,14 where they used 
70 - 150 μm drug-eluting beads, pointed out an incidence 
of PES of 67.4%, which is also in the described range 
of 60% - 80%. However, a study from Padia et al15 that 
compared the safety of small (100 - 300 μm) and medium-
size (300 - 500 μm) particles, showed that the incidence of 
postembolization syndrome was lower in the first group and 
corresponded to 8%. In our study, we also used 100 - 300 
μm beads and this rate compares better with our results. On 
the other hand, there are no specific findings or laboratory 
values to identify PES.7 The diagnosis is made clinically, 
based on the presence of some symptoms and signs in the 
post procedural period (abdominal pain, fever, nausea and/
or vomiting) and absence of other significant findings. In our 
study, we included in the PES group only the procedures that 
were associated with a prolongation of the hospitalization 
time or need for emergency department visiting and/or re-
hospitalization in the postprocedural period. This is probably 
the main reason why our PES incidence is much lower than 
the overall described 60% - 80%. However, we think that 
with these criteria we are including only the cases of PES 
that have significant clinical and economic impact. 
 In our study, we found that a doxorubicin dosage 
above 75 mg (more than one vial) is a risk factor for the 
development of PES. The maximum dose used was 150 
mg (two vials). Several previous studies also showed 
that a higher dose of chemoembolization agents (which 
also included doxorubicin) is associated with a higher risk 
of PES.5,16,17 Taking into account that the pathogenesis 
of PES is multifactorial and related to the toxicity of the 
chemotherapeutic drug itself, which also induces an 
inflammatory response,7 it is expected that a higher dose of 
chemotherapeutic drug will be associated with an increased 
risk of PES. The cut-off of one vial that we found may be 
helpful for decision making in clinical practice, whenever it 
is possible to avoid a higher dose without compromising the 
efficacy of the treatment.
 We also concluded that the size of the largest nodule 
treated is a risk factor for PES, although we could not find 
a cut-off. At least two previous studies also pointed out 
this risk factor and established a cut-off of 5 cm, above 
which the risk of PES increases.2,6 Another study by Li et 
al. demonstrated that a tumor size > 3 cm was associated 
with a higher risk of PES.16 On one hand, a larger tumor 
size is generally associated with a higher dose used, which 
we already found is a risk factor for PES development. On 
the other hand, we saw that tumor necrosis and associated 
inflammatory response are also thought to be involved in 
PES pathogenesis,7 and a larger tumor is expected to be 
associated with a higher volume of necrotized tissue, if the 
treatment is successful. 
 Our results showed that female gender is related with 
a higher risk of PES and this association was confirmed 
in multivariate logistic regression. This finding was also 
pointed out in a previous study by Siriwardana et al.2 
Another study by Wang et al18 also showed that female 
gender correlates with a higher incidence of postprocedural 
nausea, particularly in premenopausal women.18 In that 
study, they found no statistically significant difference in the 
incidences of nausea and vomiting between male over 50 
years and female patients who have entered menopause, 
a finding that raised the suspicion that these associations 
could be due to hormonal causes, namely the estradiol 
level. However, in our study, all women included both in the 
cases and control groups were postmenopausal, so this 
explanation is not applicable. Another aspect that would 
be interesting to investigate is the potential influence of 
body mass index (BMI), which is general lower in female 
patients. It was not possible to investigate this association 
in the present study since it is a retrospective study and the 
necessary data (height and weight) was not present in the 
clinical charts. We could also consider the possibility of this 
association being related with other confounding factors 
that can differ by gender, like the cause of cirrhosis. 
 In our study, the proportion of patients who had a 
previous TACE procedure was lower in the group that 
developed PES, but with no statistical significance. A 
previous study by Leung et al5 achieved similar results. 
Another study showed no relation between the number of 
previous TACE procedures and PES.6 
 The embolization of the cystic artery was also pointed 
out as a possible risk factor for the development of PES.5 
In our study, this relation was not observed, although there 
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were only three procedures associated with embolization 
of the cystic artery (two in the PES group and one in the 
control group).
 The use of additional embolics (lipiodol and/or PVA 
particles) was not associated with the risk of PES. Some 
studies showed that lipiodol dose was associated with 
the risk of PES2,6,19 and a study by Jun et al6 established a 
dose ≥ 7 ml as a cut-off. In our study, both in the PES and 
control group, the procedures in which injection of lipiodol 
occurred, the dose was always small (≤ 6 ml) and so it was 
not expected to increase the risk of PES.
 Child-Pugh and MELD scores were not associated with 
the risk of PES. A previous study also did not find relation 
between Child-Pugh score and the development of PES.6
 The presence of ascites was pointed out in a previous 
study as a potential risk factor for PES.2 In our study we did 
not find this relation, but it is important to refer that all our 
cases of ascites were of small/medium volume.
 The presence of segmental portal vein thrombosis and 
the age of the patient were not associated with PES. These 
factors were also not related to PES in previous studies.2,6
 The main limitation of our study is its retrospective 
design. We had to rely on the information of the clinical 
charts of the patients. For the definition of PES, we applied 
uniform criteria to every patient to reduce our dependence 
on the medical registrations (time of hospitalization and 
emergency department visits/re-hospitalization). But if, 
for example, a patient had resorted to another institution 
with symptoms of PES in the post-procedural period, we 
would not have access to that information if the surgeon 
did not register it in the clinical chart in the usual follow-
up appointment (one/three months after the procedure). 
Furthermore, regarding the laboratory data, we could only 
analyse the results from the blood tests performed prior 
to the procedure (that all patients do routinely). It was not 
possible to perform laboratory tests in the post-procedural 
period and relate them to the development of PES. Another 
limitation of the study is the relative small sample, although 
our initial group of participants was large, which is directly 
related to the small number of procedures associated with 
PES.
CONCLUSION
 In this study, we found that female gender is related to a 
higher incidence of PES. This association was the only one 
that was further confirmed in multivariate logistic regression. 
The reason for this association is not yet understood and 
deserves future investigation. 
 We also found that the administration of a dose of 
doxorubicin above 75 mg is associated with a higher risk 
of developing PES. This finding may be helpful for decision 
making in clinical practice, whenever it is possible to avoid 
a higher dose without compromising the efficacy of the 
treatment. The size of the largest nodule treated was also 
associated with the risk of development of PES after TACE 
for HCC treatment. 
 Age, Child-Pugh and MELD scores, number of nodules, 
embolization of the cystic artery, use of additional embolics, 
previous TACE procedures and segmental portal vein 
thrombosis were not related to the development of PES.
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